2018 Conference on Retroviruses and Opportunistic Infections*

March 4-7, 2018; Boston, Massachusetts
Get up to date on the latest HIV data with rapid Capsule Summaries, downloadable slidesets, and live, expert-led Webinars covering key studies from Boston.

New Data from CROI 2018


Boosted PI–based dual therapy provides similar safety and efficacy through 48 weeks compared with boosted PI–based triple therapy in treatment-naive patients including those with baseline HIV-1 RNA > 100,000 copies/mL.

Released: March 8, 2018

In this retrospective analysis, patients with M184V or hepatitis C virus coinfection had a significantly higher probability of viral blips.

Released: March 12, 2018

Rates of virologic rebound or virologic efficacy at Week 48 similar across subgroups of patients without history of DRV RAMs or virologic failure on DRV.

Released: March 9, 2018

Independent of the NRTI backbone, a higher rate of patients receiving second-line DTG-based ART achieved HIV-1 RNA < 400 copies/mL.

Released: March 12, 2018

Concomitant use of bisphosphonates and switch to TAF also associated with additional improvement in T-score at spine, but not at hip.

Released: March 10, 2018

HIV-1 RNA < 100 copies/mL at Day 14 in 5/8 patients receiving dolutegravir vs 1/5 receiving standard-of-care efavirenz.

Released: March 10, 2018

Overall efficacy and safety between the 2 INSTI-based, fixed-dose regimens comparable after 48 weeks.

Released: March 7, 2018

Prioritizing public health interventions for these transmission networks, particularly young Hispanic MSM, may reduce further incidences of infections

Released: March 12, 2018

Analysis suggests modifiable risk factors play a key role in increased morbidity and mortality following CKD diagnosis.

Released: March 9, 2018

Following switch from ABC, patients had increases in collagen receptor glycoprotein VI expression and soluble receptor levels.

Released: March 12, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Gilead Sciences
Janssen Therapeutics
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.